We could not find any results for:
Make sure your spelling is correct or try broadening your search.
HYMPAVZIโs approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or...
BP Plc (NYSE:BP) – BP expects a net debt increase in Q3 due to lower refining margins and changes in asset sale timing. The company faces reduced earnings of up to $600 million, signaling a...
First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer...
Tesla (NASDAQ:TSLA) – Tesla’s sales in China increased by 19.2% in September, totaling over 72,000 electric vehicles sold, its best performance of the year. Deliveries of locally...
Board of Directors approves quarterly cash dividend of $0.42 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the...
Alphabet (NASDAQ:GOOGL) – The U.S. Department of Justice is considering asking a judge to force Google to sell parts of its business to mitigate its search dominance, including Chrome and...
Presentations highlight momentum of Pfizerโs portfolio of infectious disease prevention and treatment options Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at...
U.S. stocks fell on Monday amid easing prospects of aggressive rate cuts by the Federal Reserve following a much higher than expected addition in U.S. non-payroll employment in the month of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions